注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Vincerx Pharma Inc是一家临床阶段的生命科学公司,专注于开发和肿瘤学知识,以推进新疗法,以解决癌症治疗方面未满足的医疗需求。该公司的小分子药物计划包括VIP152,这是一种选择性的、临床阶段的阳性转录延伸因子-β/细胞周期蛋白依赖性激酶9(PTEFb/CDK9)抑制剂。该公司的抗体药物偶联物(ADC)平台包括VIP943和VIP924,它们是针对已知和肿瘤目标的ADC化合物。生物偶联计划还包括VIP236,它是一种用于实体瘤的小分子药物偶联物(SMDC)。它的SMDC平台针对具有优化喜树碱的晚期实体瘤,喜树碱是一种强效细胞毒素(弹头、有效载荷或弓形虫)。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Laura I. Bushnell | 54 | 2020 | Independent Director |
Francisco D. Salva | 52 | 2020 | Independent Director |
Howard A. Burris | - | 2021 | Member of Scientific Advisory Board |
Brian J. Druker | 67 | 2020 | Independent Director |
John H. Lee | 55 | 2020 | Independent Director |
John C. Byrd | - | 2021 | Founder & Chairman of Scientific Advisory Board |
Anthony W. Tolcher | - | 2021 | Member of Scientific Advisory Board |
Ruth E. Stevens | 64 | 2021 | Independent Director |
Andre Goy | - | 2021 | Member of Scientific Advisory Board |
Apostolia Tsimberidou | - | 2024 | Member of Scientific Advisory Board |
Naval G. Daver | - | 2024 | Member of Scientific Advisory Board |
Ian W. Flinn | - | 2021 | Member of Scientific Advisory Board |
Alice Mims | - | 2024 | Member of Scientific Advisory Board |
Marina Konopleva | - | 2024 | Member of Scientific Advisory Board |
Uma Borate | - | 2024 | Member of Scientific Advisory Board |
Amer Zeidan | - | 2024 | Member of Scientific Advisory Board |
Raquel E. Izumi | 54 | 2020 | Co-Founder, President, COO, Secretary & Director |
Ahmed M. Hamdy | 59 | 2020 | Co-Founder, Chairman & CEO |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核